Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹119 Cr
Revenue (TTM)
₹97 Cr
Net Profit (TTM)
₹9 Cr
ROE
18.8 %
ROCE
16.4 %
P/E Ratio
14.9
P/B Ratio
2.2
Industry P/E
35.17
EV/EBITDA
9.2
Div. Yield
0.1 %
Debt to Equity
0.8
Book Value
₹48.2
EPS
₹7.3
Face value
10
Shares outstanding
11,050,000
CFO
₹-6.16 Cr
EBITDA
₹38.77 Cr
Net Profit
₹15.74 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sotac Pharmaceuticals
| -12.3 | -2.7 | -12.3 | -9.1 | -- | -- | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Sotac Pharmaceuticals
| 11.1 | -7.3 |
|
BSE Small Cap
| -6.6 | 29.0 |
|
BSE Healthcare
| -3.3 | 43.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sotac Pharmaceuticals
|
108.0 | 119.3 | 97.0 | 9.3 | -- | 18.8 | 14.9 | 2.2 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
2015
Chairman
Sharadkumar Dashrathbhai Patel
Managing Director
Sharadkumar Dashrathbhai Patel
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Sotac Pharmaceuticals Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Sotac Pharmaceuticals Ltd is ₹108.00 (NSE) as of 02-Apr-2026 15:18 IST. Sotac Pharmaceuticals Ltd has given a return of -9.05% in the last 1 years.
The P/E ratio of Sotac Pharmaceuticals Ltd is 14.87 times as on 01-Apr-2026, a 58 discount to its peers’ median range of 35.17 times.
The P/B ratio of Sotac Pharmaceuticals Ltd is 2.24 times as on 01-Apr-2026, a 30 discount to its peers’ median range of 3.21 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
16.35
|
2.46
|
|
2024
|
31.23
|
2.95
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Sotac Pharmaceuticals Ltd are Rs 152.35 and Rs 0.00 as of 03-Apr-2026.
Sotac Pharmaceuticals Ltd has a market capitalisation of ₹ 119 Cr as on 01-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sotac Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.